Cargando…
Management of good-risk metastatic nonseminomatous germ cell tumors of the testis: Current concepts and controversies
INTRODUCTION/METHODS: Approximately 30% of nonseminomatous germ-cell tumors (NSGCT) of the testis present with metastatic disease. In 1997, the International Germ Cell Cancer Collaborative Group (IGCCCG) stratified all patients with metastatic NSGCT into various risk groups based on serum tumor mark...
Autores principales: | Jayram, Gautam, Szmulewitz, Russell Z., Eggener, Scott E. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2878446/ https://www.ncbi.nlm.nih.gov/pubmed/20535293 http://dx.doi.org/10.4103/0970-1591.60449 |
Ejemplares similares
-
Management of post-chemotherapy residual mass in patients with metastatic nonseminomatous germ cell tumors of the testis
por: Fitzgerald, John P., et al.
Publicado: (2010) -
Management options for stage 1 nonseminomatous germ cell tumors of the testis
por: Beck, Stephen D. W.
Publicado: (2010) -
Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testis
por: Bilen, Mehmet Asim, et al.
Publicado: (2016) -
Surgical controversies in the management of post-chemotherapy nonretroperitoneal residual disease in metastatic nonseminomatous germ cell tumors
por: Pandey, Durgatosh, et al.
Publicado: (2016) -
Incidental detection of Zinner syndrome in a patient with nonseminomatous germ cell tumor of testis
por: Khoda, Jeevitesh, et al.
Publicado: (2020)